These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 8013984)

  • 41. Interferon-alpha therapy in polycythemia vera and essential thrombocythemia.
    Elliott MA; Tefferi A
    Semin Thromb Hemost; 1997; 23(5):463-72. PubMed ID: 9387205
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Contemporary approach to essential thrombocythemia and polycythemia vera.
    Aruch D; Mascarenhas J
    Curr Opin Hematol; 2016 Mar; 23(2):150-60. PubMed ID: 26717193
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Platelets and thrombosis in myeloproliferative diseases.
    Harrison CN
    Hematology Am Soc Hematol Educ Program; 2005; ():409-15. PubMed ID: 16304412
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Splenectomy after portal thrombosis in patients with polycythemia vera and essential thrombocythemia.
    Randi ML; Fabris F; Ruzzon E; Pacquola E; Cella G; Girolami A
    Haematologica; 2002 Nov; 87(11):1180-4. PubMed ID: 12414348
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Myeloproliferative syndromes: diagnosis and therapeutic options.
    Hellmann A
    Pol Arch Med Wewn; 2008 Dec; 118(12):756-60. PubMed ID: 19202955
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols.
    Berk PD; Goldberg JD; Donovan PB; Fruchtman SM; Berlin NI; Wasserman LR
    Semin Hematol; 1986 Apr; 23(2):132-43. PubMed ID: 3704665
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Management of symptoms in polycythemia vera and essential thrombocythemia patients.
    Radia D; Geyer HL
    Hematology Am Soc Hematol Educ Program; 2015; 2015():340-8. PubMed ID: 26637741
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Diagnosis and treatment of thrombocythemia in myeloproliferative disorders.
    Gilbert HS
    Oncology (Williston Park); 2001 Aug; 15(8):989-96, 998; discussion 999-1000,1006,1008. PubMed ID: 11548978
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A gain-of-function mutation of JAK2 in myeloproliferative disorders.
    Kralovics R; Passamonti F; Buser AS; Teo SS; Tiedt R; Passweg JR; Tichelli A; Cazzola M; Skoda RC
    N Engl J Med; 2005 Apr; 352(17):1779-90. PubMed ID: 15858187
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Essential thrombocytosis].
    Van Camp G
    Acta Clin Belg; 1989; 44(1):31-6. PubMed ID: 2763782
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Splenic rupture complicating periinterventional glycoprotein IIb/IIIa antagonist therapy for myocardial infarction in polycythemia vera.
    Friedrich EB; Kindermann M; Link A; Böhm M
    Z Kardiol; 2005 Mar; 94(3):200-4. PubMed ID: 15747043
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Target hematologic values in the management of essential thrombocythemia and polycythemia vera.
    Hernández-Boluda JC; Gómez M
    Eur J Haematol; 2015 Jan; 94(1):4-11. PubMed ID: 24814134
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera.
    Michiels JJ; Berneman Z; Schroyens W; Finazzi G; Budde U; van Vliet HH
    Semin Thromb Hemost; 2006 Sep; 32(6):589-604. PubMed ID: 16977569
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Anagrelide for thrombocytosis in myeloproliferative disorders: a prospective study to assess efficacy and adverse event profile.
    Steurer M; Gastl G; Jedrzejczak WW; Pytlik R; Lin W; Schlögl E; Gisslinger H
    Cancer; 2004 Nov; 101(10):2239-46. PubMed ID: 15476273
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [The treatment of myeloproliferative syndromes].
    Maurice P
    Schweiz Med Wochenschr; 1975 Oct; 105(40):1269-74. PubMed ID: 1061995
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Extreme thrombocytosis and cardiovascular surgery: risks and management.
    Natelson EA
    Tex Heart Inst J; 2012; 39(6):792-8. PubMed ID: 23304015
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The safety and performance of the Spectra Optia apheresis system platelet depletion protocol in patients with elevated platelet counts.
    Lopert P; Abdelrahman S; Graybill CA; Rhodes J; Sørensen B; Li M; Hu Y; Wu D; Liu L; He P; Zhang X; Huang F; Hu J; Bill J
    J Clin Apher; 2022 Dec; 37(6):544-552. PubMed ID: 36102144
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Polycythemia vera and essential thrombocythemia in young patients.
    Frezzato M; Ruggeri M; Castaman G; Rodeghiero F
    Haematologica; 1993; 78(6 Suppl 2):11-7. PubMed ID: 8039752
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Molecular genetic evaluation of myeloproliferative neoplasms.
    Azzato EM; Bagg A
    Int J Lab Hematol; 2015 May; 37 Suppl 1():61-71. PubMed ID: 25976962
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Thrombocytapheresis in Patient with Essential Thrombocythemia: A Case Report.
    Elhassan AM; Alsaud A; Yassin MA; Aldapt M; Riaz L; Ghori F; Bin Ahmad A; Abdulla M
    Case Rep Oncol; 2020; 13(2):675-679. PubMed ID: 32774255
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.